Passage Bio 미래 성장

NasdaqGS:PASG - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	N/A	-75	N/A	N/A	4
12/31/2025	N/A	-68	N/A	N/A	5
12/31/2024	N/A	-68	N/A	N/A	5
9/30/2024	N/A	-69	N/A	N/A	N/A
6/30/2024	N/A	-77	-71	-71	N/A
3/31/2024	N/A	-84	-75	-75	N/A
12/31/2023	N/A	-102	-78	-78	N/A
9/30/2023	N/A	-112	-83	-83	N/A
6/30/2023	N/A	-112	-89	-87	N/A
3/31/2023	N/A	-128	-99	-96	N/A
12/31/2022	N/A	-136	-123	-118	N/A
9/30/2022	N/A	-160	-137	-125	N/A
6/30/2022	N/A	-180	-165	-143	N/A
3/31/2022	N/A	-189	-167	-141	N/A
12/31/2021	N/A	-185	-153	-127	N/A
9/30/2021	N/A	-173	-145	-126	N/A
6/30/2021	N/A	-155	-110	-102	N/A
3/31/2021	N/A	-134	-92	-89	N/A
12/31/2020	N/A	-112	-82	-81	N/A
9/30/2020	N/A	-86	-69	-69	N/A
6/30/2020	N/A	-69	-63	-62	N/A
3/31/2020	N/A	-56	-62	-62	N/A
12/31/2019	N/A	-46	-42	-40	N/A
9/30/2019	N/A	-38	-45	-41	N/A

애널리스트 미래 성장 예측

수입 대 저축률: PASG 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: PASG 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: PASG 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: PASG 은(는) 내년에 수익이 없을 것으로 예상됩니다.

고성장 수익: PASG 은(는) 내년에 수익이 없을 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: PASG 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

Passage Bio 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Price target increased by 9.5% to US$7.67

Price target increased by 27% to US$7.00

Price target decreased by 23% to US$5.40

Price target decreased by 20% to US$7.00

Price target increased by 9.9% to US$8.17

Price target increased by 9.3% to US$8.33

Recent updates

Passage Bio, Inc. Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy 31st Annual Conference

Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

Passage Bio, Inc. to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in FTD-GRN in upliFT-D Study at 14th International Conference on Frontotemporal Dementias

Passage Bio, Inc. Appoints Thomas Kassberg as Class I Director and Member of the Audit Committee of the Board

Price target increased by 9.5% to US$7.67

Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients

Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

New minor risk - Shareholder dilution

Passage Bio, Inc., Annual General Meeting, May 21, 2024

Passage Bio, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

We're Keeping An Eye On Passage Bio's (NASDAQ:PASG) Cash Burn Rate

Price target increased by 27% to US$7.00

Passage Bio, Inc. Announces Promising Initial Data from Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities

Price target decreased by 23% to US$5.40

Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

Passage Bio, Inc. Receives Non-Compliance Notice From Nasdaq

Passage Bio, Inc. Receives Non-Compliance Notice From Nasdaq

Price target decreased by 20% to US$7.00

Passage Bio, Inc. Announces New Interim Safety, Biomarker, and Survival Data from Cohorts 1-4 in Imagine-1 Clinical Study

Passage Bio, Inc. Announces Executive Changes

Price target increased by 9.9% to US$8.17

We Think Passage Bio (NASDAQ:PASG) Needs To Drive Business Growth Carefully

Price target increased by 9.3% to US$8.33

Passage Bio, Inc. Announces Positive Interim Clinical Data from First Six Patients with GM1 Gangliosidosis in Imagine-1 Study

High number of new directors

Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

Passage Bio, Inc. Announces Resignation of Maxine Gowen as Interim Executive Chairwoman

Passage Bio, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Passage Bio, Inc. Announces Executive Changes

Passage appoints William Chou CEO

Passage Bio Doses First Patient in Global Clinical Trial of PBFT02 Gene Therapy for Frontotemporal Dementia with Granulin Mutations

Passage Bio GAAP EPS of -$0.73 beats by $0.09

High number of new directors

Passage Bio, Inc. Appoints Michael Kamarck to Board of Directors

Passage Bio, Inc.(NasdaqGS:PASG) dropped from Russell 2000 Dynamic Index

Passage Bio, Inc. Receives FDA Clearance of IND Application for PBML04 for Treatment of Metachromatic Leukodystrophy

We're A Little Worried About Passage Bio's (NASDAQ:PASG) Cash Burn Rate

Passage Bio, Inc. Announces Management Changes

Passage Bio, Inc. Presents New Interim Clinical and Biomarker Data for Patients with GM1 Gangliosidosis in Imagine-1 Study At ASGCT 25Th Annual Meeting

Passage Bio, Inc. to Report Q1, 2022 Results on May 16, 2022

High number of new directors

Passage Bio, Inc., Annual General Meeting, May 26, 2022

Passage Bio: Worth Keeping An Eye On

Passage Bio, Inc. Announces Publication of Preclinical Data that Support Ongoing Clinical Study of PBKR03 in Krabbe Disease

Passage Bio, Inc. to Report Q4, 2021 Results on Mar 03, 2022

Passage Bio Presents New Interim Clinical Data for Patients with Gm1 Gangliosidosis in Imagine-1 Study At 2022 Worldsymposium

Price target decreased to US$23.38

Passage Bio Announces Positive Interim Safety and Biomarker Data and Advances Phase 1/2 Trial of PBGM01 in GM1 Gangliosidosis

Will Passage Bio (NASDAQ:PASG) Spend Its Cash Wisely?

Passage Bio Announces Pipeline Expansion and Clinical Program Update

Passage Bio (NASDAQ:PASG) Is In A Good Position To Deliver On Growth Plans

Independent Chairman of the Board Tadataka Yamada has left the company

Independent Chairman of the Board Tadataka Yamada has left the company

Passage Bio, Inc.(NasdaqGS:PASG) dropped from Russell 2500 Growth Index

Passage Bio: Price Reduced, But Without Data, Does Not Look Convincing

Independent Director Patrick Heron has left the company

Chief Financial Officer has left the company

Chief Medical Officer has left the company

Passage Bio Announces Pre-Clinical Data Presentation at Annual ASGCT Meeting

Passage Bio partners with InformedDNA to offer counseling, testing for early dementia

Chief Medical Officer notifies of intention to sell stock

Passage Bio, Inc. Announces U.S. Food and Drug Administration Grants Fast Track Designation to Three Passage Bio Gene Therapy Candidates Targeting Rare CNS Disorders

We're Hopeful That Passage Bio (NASDAQ:PASG) Will Use Its Cash Wisely

Passage Bio, Inc. to Report Q4, 2020 Results on Mar 03, 2021

New 90-day low: US$18.13

Passage Bio, Inc. Announces Board Changes

FDA Clears IND Application for Passage Bio’s Gene Therapy Candidate PBKR03 for Treatment of Patients with Early Infantile Krabbe Disease

Do Institutions Own Passage Bio, Inc. (NASDAQ:PASG) Shares?

Passage Bio, Inc. Receives FDA Clearance of IND Application for PBFT02 Gene Therapy Candidate for Treatment of Patients with Frontotemporal Dementia with Granulin Mutations